Smith I E, al-Moundhri M
Department of Medicine, Royal Marsden Hospital, London, UK.
Biomed Pharmacother. 1998;52(3):116-21. doi: 10.1016/S0753-3322(98)80089-9.
Primary (neoadjuvant) chemotherapy is a rapidly evolving area in the management of early operable breast cancer. This approach achieves significant responses in around 80% of patients, with a reduction in the need for immediate mastectomy in patients presenting with large primaries, with no evidence of increased local recurrence. So far randomised trials suggest that survival is as good with primary chemotherapy as with post-operative adjuvant chemotherapy. Primary chemotherapy offers the potential short term tumour response as a predictor for longer term survival. More importantly, it allows serial biological measurements of treated breast cancers which, in turn, may aid the selection of appropriate treatment for individual patients and allow the rapid assessment of new therapies.
原发性（新辅助）化疗是早期可手术乳腺癌治疗中一个快速发展的领域。这种方法在约80%的患者中取得了显著疗效，减少了初诊时肿瘤较大患者立即进行乳房切除术的需求，且无局部复发增加的证据。到目前为止，随机试验表明，原发性化疗的生存率与术后辅助化疗相同。原发性化疗提供了短期肿瘤反应这一潜在的长期生存预测指标。更重要的是，它允许对接受治疗的乳腺癌进行系列生物学检测，这反过来可能有助于为个体患者选择合适的治疗方法，并能快速评估新疗法。
